In last trading session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw 1.64 million shares changing hands with its beta currently measuring 1.28. Company’s recent per share price level of $2.49 trading at $0.05 or 2.05% at ring of the bell on the day assigns it a market valuation of $609.88M. That closing price of LXRX’s stock is at a discount of -52.21% from its 52-week high price of $3.79 and is indicating a premium of 63.05% from its 52-week low price of $0.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.5 million shares which gives us an average trading volume of 4.70 million if we extend that period to 3-months.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Upright in the green during last session for gaining 2.05%, in the last five days LXRX remained trading in the green while hitting it’s week-highest on Friday, 03/15/24 when the stock touched $2.49 price level, adding 4.96% to its value on the day. Lexicon Pharmaceuticals Inc’s shares saw a change of 62.75% in year-to-date performance and have moved 0.40% in past 5-day. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) showed a performance of -6.04% in past 30-days. Number of shares sold short was 21.07 million shares which calculate 3.71 days to cover the short interests.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Statistics highlight that Lexicon Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 104.94% of value to its shares in past 6 months, showing an annual growth rate of 10.13% while that of industry is 12.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -17.60% in the current quarter and calculating 18.20% increase in the next quarter. This year revenue growth is estimated to rise 2,043.70% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.37 million for the same. And 3 analysts are in estimates of company making revenue of $2.97 million in the next quarter that will end on Jun 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.96% during past 5 years.
LXRX Dividends
Lexicon Pharmaceuticals Inc is more likely to be releasing its next quarterly report between April 30 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders are in possession of 1.65% of company’s total shares while institution are holding 77.58 percent of that, with stock having share float percentage of 78.88%. Investors also watch the number of corporate investors in a company very closely, which is 77.58% institutions for Lexicon Pharmaceuticals Inc that are currently holding shares of the company. Artal Group S.A. is the top institutional holder at LXRX for having 117.55 million shares of worth $269.2 million. And as of Jun 29, 2023, it was holding 48.00% of the company’s outstanding shares.
The second largest institutional holder is BVF Inc., which was holding about 20.0 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 8.16% of outstanding shares, having a total worth of $45.79 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 3.7 million shares of worth $8.48 million or 1.51% of the total outstanding shares. The later fund manager was in possession of 2.53 million shares on Aug 30, 2023, making its stake of worth around $4.35 million in the company or a holder of 1.03% of company’s stock.
